Merrill Lynch analyst Tazeen Ahmad maintained a Buy rating on Alnylam Pharmaceuticals on Thursday, setting a price target of $157, which is approximately 9.10% above the present share price of $143.91.
Ahmad expects Alnylam Pharmaceuticals to post earnings per share (EPS) of -$1.56 for the fourth quarter of 2020.
The current consensus among 13 TipRanks analysts is for a Strong Buy rating of shares in Alnylam Pharma (NASDAQ:ALNY), with an average price target of $167.33.
The analysts price targets range from a high of $225 to a low of $90.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $103.96 million and a net profit of -$198.86 million. The company's market cap is $16.69 billion.
According to TipRanks.com, Merrill Lynch analyst Tazeen Ahmad is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 20.5% and a 53.39% success rate.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp (OTC:SHCAY) on June 14, 2002 and is headquartered in Cambridge, MA.